Publication | Closed Access

Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience

Hematological MalignancyNeuro-oncologyNovel Anti-myeloma AgentsMedicineMalignant Blood DisorderSurvival ImprovementHematologyMultiple MyelomaNeurologyOncologyMyelopoiesis